Doxorubicin
Checked 2026-09-09
Advanced soft-tissue sarcoma, first line
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 75 mg/m² | IV | D1 |
Cycles
6 (cumulative dose 450 mg/m²)
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Consider (10-20% FN risk)
Notes
- Doxorubicin + ifosfamide (AIM) adds response rate but not survival; reserve for symptomatic bulk or neoadjuvant use (ISG-STS 1001).
Used in
Products
Source
EORTC 62012, Lancet Oncology 2014
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.